FGFR1, also named as CD331, is a receptor tyrosine kinase belonging to the fibroblast growth factor receptor family. Somatic mutations and amplification of FGFR1 gene are thought to contribute to various types of cancers. The identification of FGFR1 as a driver gene has led to the development of anticancer therapeutics agents, including futibatinib (TAS-120), AZD4547, infigratinib (BGJ398) and pemigatinib (INCB054828).
Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.